Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 2/2011

01-03-2011 | Review

Inflammation and transplantation tolerance

Author: Daniel R. Goldstein

Published in: Seminars in Immunopathology | Issue 2/2011

Login to get access

Abstract

Although our understanding of the immunological mechanisms of transplant tolerance induction has greatly improved, how the innate immune system impacts transplant tolerance has only been recently appreciated. In this review, the involvement of the innate immune receptors, Toll-like receptors (TLRs), in both experimental models of acute allograft rejection and transplant tolerance induction in addition to clinical studies of organ transplantation are described. Several inflammatory cytokines, including IL-6, TNF-α, and type I interferons, which are induced by TLRs and other activators of innate immunity, prevent transplant tolerance induction. Their induction may be provoked by environmental exposures, such as viral or bacterial infections. Further investigation as to the innate inflammatory basis that controls the balance between immune acceptance and allograft rejection may lead us closer to the elusive goal of transplant tolerance acquisition.
Literature
1.
Wekerle T, Kurtz J, Bigenzahn S, Takeuchi Y, Sykes M (2002) Mechanisms of transplant tolerance induction using costimulatory blockade. Curr Opin Immunol 14:592–600PubMedCrossRef
2.
Walsh PT, Taylor DK, Turka LA (2004) Tregs and transplantation tolerance. J Clin Invest 114:1398–1403PubMed
3.
Dai Z, Lakkis FG (1999) The role of cytokines, CTLA-4 and costimulation in transplant tolerance and rejection. Curr Opin Immunol 11:504–508PubMedCrossRef
4.
Brook MO, Wood KJ, Jones ND (2006) The impact of memory T cells on rejection and the induction of tolerance. Transplantation 82:1–9PubMedCrossRef
5.
Adams AB, Williams MA, Jones TR, Shirasugi N, Durham MM, Kaech SM et al (2003) Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 111:1887–1895PubMed
6.
Selin LK, Brehm MA, Naumov YN, Cornberg M, Kim S-K, Clute SC et al (2006) Memory of mice and men: CD8+ T-cell cross-reactivity and heterologous immunity. Immunol Rev 211:164–181PubMedCrossRef
7.
8.
9.
Taro Kawai SA (2008) Toll-like receptor and RIG-1-like receptor signaling. Ann NY Acad Sci 1143:1–20PubMedCrossRef
10.
Fritz JH, Ferrero RL, Philpott DJ, Girardin SE (2006) Nod-like proteins in immunity, inflammation and disease. Nat Immunol 7:1250–1257PubMedCrossRef
11.
Dalod M, Salazar-Mather TP, Malmgaard L, Lewis C, Asselin-Paturel C, Briere F et al (2002) Interferon alpha/beta and interleukin 12 responses to viral infections: pathways regulating dendritic cell cytokine expression in vivo. J Exp Med 195:517–528PubMedCrossRef
12.
Kawai T, Akira S (2007) SnapShot: pattern-recognition receptors. Cell 129:1024.e1021–1024.e1022CrossRef
13.
Goldstein DR, Tesar BM, Akira S, Lakkis FG (2003) Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest 111:1571–1578PubMed
14.
Tesar BM, Zhang J, Li Q, Goldstein DR (2004) TH1 immune responses to fully mhc mismatched allografts are diminished in the absence of Myd88, a toll-like receptor signal adaptor protein. Am J Transplant 4:1429–1439PubMedCrossRef
15.
Goldberg A, Parolini M, Chin BY, Czismadia E, Otterbein LE, Bach FH et al (2007) Toll-like receptor 4 suppression leads to islet allograft survival. FASEB J 21:2840–2848PubMedCrossRef
16.
Palmer SM, Burch LH, Davis RD, Herczyk WF, Howell DN, Reinsmoen NL et al (2003) The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med 168:628–632PubMedCrossRef
17.
Ducloux D, Deschamps M, Yannaraki M, Ferrand C, Bamoulid J, Saas P et al (2005) Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney Int 67:2454–2461PubMedCrossRef
18.
Kruger B, Krick S, Dhillon N, Lerner SM, Ames S, Bromberg JS et al (2009) Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci 106:3390–3395PubMedCrossRef
19.
Goldstein DR (2007) The identity of innate immune activators in organ transplantation: origins from within or exterior to the host? Am J Transplant 7:1692–1694PubMedCrossRef
20.
Shirali A, Goldstein DR (2008) Activation of the innate immune system by the endogenous ligand hyaluronan. Curr Opin Organ Transpl 13:20–25CrossRef
21.
Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T et al (2002) Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 195:99–111PubMedCrossRef
22.
Tesar BM, Jiang D, Liang J, Palmer SM, Noble PW, Goldstein DR (2006) The role of hyaluronan degradation products as innate alloimmune agonists. Am J Transplant 6:2622–2635PubMedCrossRef
23.
Johnson GB, Brunn GJ, Platt JL (2004) Cutting edge: an endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through toll-like receptor 4. J Immunol 172:20–24PubMed
24.
Smiley ST, King JA, Hancock WW (2001) Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4. J Immunol 167:2887–2894PubMed
25.
Shi Y, Evans J, Rock K (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425:516–521PubMedCrossRef
26.
Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT et al (2005) The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 201:1135–1143PubMedCrossRef
27.
Jang HR, Rabb H (2009) The innate immune response in ischemic acute kidney injury. Clin Immunol 130:41–50PubMedCrossRef
28.
Rouschop KMA, Roelofs JJTH, Claessen N, Martins PdC, Zwaginga J-J, Pals ST et al (2005) Protection against renal ischemia reperfusion injury by CD44 disruption. J Am Soc Nephrol 16:2034–2043PubMedCrossRef
29.
Shishido T, Nozaki N, Yamaguchi S, Shibata Y, Nitobe J, Miyamoto T et al (2003) Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 108:2905–2910PubMedCrossRef
30.
Balistreri CR, Candore G, Colonna-Romano G, Lio D, Caruso M, Hoffmann E et al (2004) Role of toll-like receptor 4 in acute myocardial infarction and longevity. JAMA 292:2339–2340, %R 101001/jama292192339PubMedCrossRef
31.
Edfeldt K, Bennet AM, Eriksson P, Frostegard J, Wiman B, Hamsten A et al (2004) Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction. Eur Heart J 25:1447–1453PubMedCrossRef
32.
Walker WE, Nasr IW, Camirand G, Tesar BM, Booth CJ, Goldstein DR (2006) Absence of innate MyD88 signaling promotes inducible allograft acceptance. J Immunol 177:5307–5316PubMed
33.
Braudeau C, Ashton-Chess J, Giral M, Dugas ELS, Pallier A, Braud C et al (2008) Contrasted blood and intragraft toll-like receptor 4 mRNA profiles in operational tolerance versus chronic rejection in kidney transplant recipients. Transplantation 86:130–136PubMedCrossRef
34.
Sutmuller RPM, den Brok MHMGM, Kramer M, Bennink EJ, Toonen LWJ, Kullberg B-J et al (2006) Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 116:485–494PubMedCrossRef
35.
Kubo T, Hatton RD, Oliver J, Liu X, Elson CO, Weaver CT (2004) Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells. J Immunol 173:7249–7258PubMed
36.
Liu H, Komai-Koma M, Xu D, Liew FY (2006) Toll-like receptor 2 signaling modulates the functions of CD4 + CD25+ regulatory T cells. Proc Natl Acad Sci 103:7048–7053PubMedCrossRef
37.
Pasare C, Medzhitov R (2003) Toll pathway-dependent blockade of CD4 + CD25+ T cell-mediated suppression by dendritic cells. Science 299:1033–1036PubMedCrossRef
38.
Chen L, Wang T, Zhou P, Ma L, Yin D, Shen J et al (2006) TLR engagement prevents transplantation tolerance. Am J Transplant 6:2282–2291PubMedCrossRef
39.
Thornley TB, Brehm MA, Markees TG, Shultz LD, Mordes JP, Welsh RM et al (2006) TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts. J Immunol 176:1561–1570PubMed
40.
Konieczny BT, Dai Z, Elwood ET, Saleem S, Linsley PS, Baddoura FK et al (1998) IFN-gamma is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. J Immunol 160:2059–2064PubMed
41.
Dai Z, Konieczny BT, Lakkis FG (2000) The dual role of IL-2 in the generation and maintenance of CD8+ memory T cells. J Immunol 165:3031–3036PubMed
42.
Samoilova EB, Horton JL, Hilliard B, Liu T-ST, Chen Y (1998) IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of il-6 in the activation and differentiation of autoreactive T cells. J Immunol 161:6480–6486PubMed
43.
Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y et al (2004) Distinct contribution of IL-6, TNF-{alpha}, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest 114:582–588PubMed
44.
Shen H, Goldstein DR (2009) IL-6 and TNF-{alpha} synergistically inhibit allograft acceptance. J Am Soc Nephrol 5:1032–1040CrossRef
45.
Suzuki N, Suzuki S, Duncan GS, Millar DG, Wada T, Mirtsos C et al (2002) Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature 416:750–756PubMedCrossRef
46.
Liu YJ (2005) IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23:275–306PubMedCrossRef
47.
Thornley TB, Phillips NE, Beaudette-Zlatanova BC, Markees TG, Bahl K, Brehm MA et al (2007) Type 1 IFN mediates cross-talk between innate and adaptive immunity that abrogates transplantation tolerance. J Immunol 179:6620–6629PubMed
48.
Wang T, Chen L, Ahmed E, Ma L, Yin D, Zhou P et al (2008) Prevention of allograft tolerance by bacterial infection with Listeria monocytogenes. J Immunol 180:5991–5999PubMed
49.
Vilchez RA, McCurry K, Dauber J, Lacono A, Griffith B, Fung J et al (2002) Influenza virus infection in adult solid organ transplant recipients. Am J Transplant 2:287–291PubMedCrossRef
50.
Soderberg-Naucler C, Emery VC (2001) Viral infections and their impact on chronic renal allograft dysfunction. Transplantation 71:SS24–SS30PubMed
51.
Koskinen PK, Kallio EA, Tikkanen JM, Sihvola RK, Hayry PJ, Lemstrom KB (1999) Cytomegalovirus infection and cardiac allograft vasculopathy. Transpl Infect Dis 1:115–126PubMedCrossRef
52.
Gabriel R, Selwyn S, Brown D, Crossland JM, Loughridge LW, Morgan MN et al (1976) Virus infections and acute renal transplant rejection. Nephron 16:282–286PubMedCrossRef
53.
Weaver CT, Murphy KM (2007) The central role of the Th17 lineage in regulating the inflammatory/autoimmune axis. Semin Immunol 19:351–352PubMedCrossRef
54.
Weaver CT, Hatton RD, Mangan PR, Harrington LE (2007) IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 25:821–852PubMedCrossRef
55.
Burrell BE, Csencsits K, Lu G, Grabauskiene S, Bishop BK (2008) CD8+ Th17 mediate costimulation blockade-resistant allograft rejection in T-bet-deficient mice. J Immunol 181:3906–3914PubMed
56.
Yuan X, Ansari MJ, D’Addio F, Paez-Cortez J, Schmitt I, Donnarumma M et al (2009) Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells. Proc Natl Acad Sci 106:10734–10739PubMedCrossRef
Metadata
Title
Inflammation and transplantation tolerance
Author
Daniel R. Goldstein
Publication date
01-03-2011
Publisher
Springer-Verlag
Published in
Seminars in Immunopathology / Issue 2/2011
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-011-0251-2

Other articles of this Issue 2/2011

Seminars in Immunopathology 2/2011 Go to the issue

Review

Role of Th17 cells and IL-17 in lung transplant rejection

Introduction

Transplantation and tolerance

Review

Clinical transplantation tolerance

Review

Special issues in the management and selection of the donor for lung transplantation

Review

The role of innate immunity in donor organ procurement

Review

Lung transplantation: infection, inflammation, and the microbiome
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits